3/25/2025

Levofloxacin Injection in 5% Dextrose

Products Affected - Description

- Levofloxacin in 5% Dextrose intravenous solution for injection, Baxter, 250 mg/50 mL, flexible container, 24 count, NDC 36000-0046-24 - discontinued
- Levofloxacin in 5% Dextrose intravenous solution for injection, Baxter, 500 mg/100 mL, flexible container, 24 count, NDC 36000-0047-24 - discontinued
- Levofloxacin in 5% Dextrose intravenous solution for injection, Baxter, 750 mg/150 mL, flexible container, 24 count, NDC 36000-0048-24 - discontinued
- Levofloxacin in 5% Dextrose intravenous solution for injection, Hikma, 250 mg/50 mL, flexible container, 24 count, NDC 00143-9722-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, Hikma, 500 mg/100 mL, flexible container, 24 count, NDC 00143-9721-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, Hikma, 750 mg/150 mL, flexible container, 24 count, NDC 00143-9720-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, Pfizer, 250 mg/50 mL, flexible container, 24 count, NDC 00409-2220-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, Pfizer, 500 mg/100 mL, flexible container, 24 count, NDC 00409-3330-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, Pfizer, 750 mg/150 mL, flexible container, 24 count, NDC 00409-4444-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, Sagent, 250 mg/50 mL, flexible container, 24 count, NDC 25021-0132-81
- Levofloxacin in 5% Dextrose intravenous solution for injection, Sagent, 500 mg/100 mL, flexible container, 24 count, NDC 25021-0132-82
- Levofloxacin in 5% Dextrose intravenous solution for injection, Sagent, 750 mg/150 mL, flexible container, 24 count, NDC 25021-0132-83
- Levofloxacin in 5% Dextrose intravenous solution for injection, WG Critical Care, 250 mg/50 mL, flexible container, 24 count, NDC 44567-0435-24
- Levofloxacin in 5% Dextrose intravenous solution for injection, WG Critical Care, 500 mg/100 mL, flexible container, 24 count, NDC 44567-0436-24

Reason for the Shortage

- Baxter has discontinued levofloxacin premixed bags.
- Hikma did not provide a reason for the shortage.
- Pfizer states the shortage is due to a manufacturing delay.
- Sagent did not provide a reason for the shortage.
- WG Critical Care did not provide a reason for the shortage.

Available Products

- Levofloxacin in 5% Dextrose intravenous solution for injection, WG Critical Care, 750 mg/150 mL, flexible container, 24 count, NDC 44567-0437-24

Estimated Resupply Dates

- Hikma has levofloxacin 250 mg/50 mL, 500 mg/100 mL, and 750 mg/150 mL premixed bags on back order and the company estimates a release date of early-August 2025 for the 250 mg bags, mid-September 2025 for the 500 mg bags, and late-March 2025 for the 750 mg bags.
- Pfizer has levofloxacin 250 mg/50 mL premixed bags and 750 mg/150 mL premixed bags available in limited supply. The 500 mg/100 mL premixed bags are on back order and the company estimates a release date of March 2025.
- Sagent has levofloxacin 250 mg/50 mL and 500 mg/100 mL premixed bags on back order and the company estimates a release date of March 2025. The 750 mg/150 mL premixed bags are on a limited allocation.
- WG Critical Care has levofloxacin 250 mg/50 mL premixed bags on back order and the company cannot estimate a release date. The 500 mg/100 mL premixed bags are on intermittent back order and the company is releasing product as it becomes available.

Updated

Updated March 25, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 29, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.